Provided by Tiger Trade Technology Pte. Ltd.

Adaptimmune Therapeutics PLC

0.0549
0.0000
Volume:- -
Turnover:- -
Market Cap:14.55M
PE:-0.08
High:0.0549
Open:0.0549
Low:0.0549
Close:0.0549
52wk High:0.8100
52wk Low:0.0403
Shares:265.05M
Float Shares:183.08M
Volume Ratio:- -
T/O Rate:- -
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.6574
EPS(LYR):-0.2807
ROE:-1341.10%
ROA:-40.86%
PB:-0.21
PE(LYR):-0.20

Loading ...

Company Profile

Company Name:
Adaptimmune Therapeutics PLC
Exchange:
NASDAQ
Establishment Date:
- -
Employees:
- -
Office Location:
- -
Zip Code:
- -
Phone:
- -
Fax:
- -
Introduction:
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers. The company has strategic collaboration and license agreement with Genentech, Inc. and F. Hoffman-La Roche Ltd to develop personalized allogeneic and allogeneic T-cell therapies; co-development collaboration agreement with Universal Cells, Inc.; third-party collaborations with Noile-Immune and Alpine Immune Sciences; and strategic alliance agreement with the MD Anderson Cancer Center. Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom.